When a company agrees to a takeover at a fixed price, you might expect its shares to trade at exactly that price.
In practice, they almost never do.
Qube Holdings Ltd (ASX: QUB) is a textbook example of this phenomenon right now.
Macquarie Asset Management has made a binding offer of $5.20 per share for Qube, valuing Australia's largest integrated logistics provider at approximately $11.7 billion.
Yet today, Qube shares trade at approximately $5.02, a discount of around 3.5% to the offer price.
That gap is the price investors pay for the uncertainty that surrounds any takeover before it formally completes.
Image source: Getty Images
What is merger arbitrage?
The strategy of buying shares in a takeover target below the offer price and waiting to receive the full consideration at completion is known as merger arbitrage.
It is a well-established investment approach used by professional fund managers and sophisticated investors around the world.
The return profile is asymmetric.
If the deal completes as planned, investors who bought Qube at $5.02 today will receive $5.20 per share, delivering a return of approximately 3.5%.
If the deal collapses for any reason, the share price will likely fall sharply back toward its pre-offer level of $4.07, delivering a loss of approximately 19% from today's price.
That asymmetry is the reason the discount exists.
The market is pricing in a small but material probability that the deal does not proceed.
Why does the discount exist?
Several factors explain why Qube trades below the $5.20 offer price despite the board's unanimous recommendation and the deal being fully funded with no financing condition.
The first is regulatory risk.
The deal requires approval from the Australian Competition and Consumer Commission, the Supreme Court of New South Wales, and the Foreign Investment Review Board.
While none of these approvals is expected to be a major hurdle given Macquarie's long track record of completing similar transactions, the process takes time and carries a non-zero risk of complication.
The second is shareholder vote risk.
Qube's shareholders must vote to approve the scheme at a meeting expected around June 2026.
The deal requires approval from 75% of votes cast, excluding UniSuper, which is rolling its stake into the new structure.
While the board's unanimous recommendation makes approval highly likely, it is not guaranteed.
The third is the time value of money.
Even if the deal completes exactly as planned by December 2026, investors tying up capital for six to seven months at a 3.5% return are earning a modest annualised return.
The shareholder vote is expected in June 2026, which annualises the 3.5% gain to approximately 10%.
This is a more attractive number, though investors should note that annualised figures assume a clean and timely completion.
The franking credit kicker
One detail that makes the Qube situation particularly interesting for Australian investors is the dividend component.
Qube is permitted to pay up to $0.40 per share in dividends before and immediately after the deal closes, which will be deducted from the $5.20 cash consideration.
The first instalment, a regular fully-franked interim dividend of $0.0535 per share, was already paid on 9 April 2026 and has been deducted from the offer price accordingly.
The more interesting component is a potential special fully-franked dividend that Qube's board intends to declare following scheme effectiveness, a structure made possible by a special ASX waiver granted on 22 April 2026.
For eligible Australian taxpayers who can utilise franking credits in full, those credits are worth approximately $0.17 per share for every $0.40 in dividends paid, effectively pushing the total economic return above the headline $5.20 figure.
Furthermore, if the deal extends past December 2026, Macquarie has agreed to pay a ticking fee of two cents per share per month, compensating investors for any delay and ensuring the annualised return does not deteriorate if the timeline slips.
The risks worth knowing
Merger arbitrage is not risk-free, and investors should approach it with clear eyes.
The biggest risk in the Qube situation is not regulatory or shareholder approval but rather a material adverse change to the business.
The deal contains a standard material adverse change clause, meaning Macquarie could walk away if Qube's business deteriorates significantly before completion.
Qube has already flagged a $10 to $20 million EBITA impact from Middle East conflict disruptions and a further $3 to $5 million from weather events in its most recent trading update, though management maintained its expectation of full-year earnings growth.
Whether those impacts rise to the level of a material adverse change is a judgement call, but on current evidence, they appear well within normal business variation.
Foolish Takeaway
Qube Holdings trading at a 3.5% discount to its takeover price is not an oversight by the market.
It reflects real, if modest, uncertainty about whether a deal that looks highly likely to proceed will actually do so on the expected timeline.
For investors who understand merger arbitrage and are comfortable with the asymmetric risk profile, the current gap between Qube's share price and the $5.20 offer price could represent an interesting low-risk return opportunity, particularly when the franking credit kicker and ticking fee protections are factored in.
For those who are not, simply understanding why the discount exists is a valuable lesson in how financial markets price risk.
